Gilmartin Capital focuses on private investments in mid-stage opportunities within the medical device, life science tools, diagnostic, and digital health sectors. Their strategy involves backing innovative platforms that address large or underserved diseases, accelerate scientific discovery, and impact the cost, site, and delivery of care, leveraging their extensive network and expertise to support growth.
75% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (1 deals in the last 12 months vs 2 prior). Average disclosed round size is $97.5M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$650M
Top Stage
Series E
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Galvanize Therapeutics | Series C | $100M | Sep 2025 |
| SShoulder Innovations | Series E | $40M | Mar 2025 |
 Insightec | Growth | $150M | Jun 2024 |
| Galvanize Therapeutics | Series B | $100M | Sep 2022 |
Top Co-Investors
Apple Tree Partners2 shared
Intuitive Surgical2 shared
Ally Bridge Group2 shared
U.S. Venture Partners1 shared
Gilde Healthcare1 shared
Aperture Venture Partners1 shared
Sectoral Asset Management1 shared
Nexus NeuroTech Ventures1 shared
Baillie Gifford1 shared
Catalio Capital Management1 shared
Perceptive Advisors1 shared
Norwest Venture Partners1 shared
T. Rowe Price1 shared
Sofinnova Partners1 shared
Janus Henderson Investors1 shared
Last updated: 12 April 2026